伊班膦酸治疗脑瘫和脊柱裂患者中期骨密度动态分析

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

论证：近年来，二膦酸盐越来越多地用于预防和治疗患有神经肌肉疾病的儿童骨质疏松症。

目的是研究伊班膦酸治疗脑瘫和脊柱裂患者中期骨密度动态分析。

材料与方法。对34例患者进行了检查和治疗：19例脑瘫（GMFCS III-IV 级）和15例儿童脊柱裂
（胸椎和上腰椎神经节段）。平均年龄9.8 ± 2.9岁。所有儿童均连续注射伊班膦酸（每3-4个月，
每1公斤体重0.1毫克，持续一年）。使用双能照X光骨密度仪评估骨组织矿物密度，在第一次输液前和每次后续输液前都用照X光密度仪进行。

结果。全身Z标准平均值从-2.55增加到-2.1，腰椎z标准平均值从-2.7增加到-1.65。腰椎区域的Z标准在第一次灌注后得到改善，在前两次灌注后得到全身Z标准的改善。

结论。在注射伊班膦酸的背景下，中期随访脑瘫和脊柱裂患者全身和腰椎的骨密度均有改善。根据确定的动力学，建议在第一次输液后3个月增加脊柱的静态负荷，在6个月后增加下肢的静态负荷。

作者简介

Vladimir Kenis

The Turner Scientific Research Institute for Children’s Orthopedics

编辑信件的主要联系方式.
Email: kenis@mail.ru
ORCID iD: 0000-0002-7651-8485
SPIN 代码: 5597-8832
Scopus 作者 ID: 36191914200
http://www.rosturner.ru/kl4.htm

MD, PhD, D.Sc., Professor, Deputy Director of Development and International Relations, Head of the Department of Foot Pathology, Neuroorthopedics and Systemic Diseases

俄罗斯联邦, 64, Parkovaya str., Saint-Petersburg, Pushkin, 196603

Andrei Sapogovskiy

The Turner Scientific Research Institute for Children’s Orthopedics

Email: sapogovskiy@gmail.com
ORCID iD: 0000-0002-5762-4477
SPIN 代码: 2068-2102
Scopus 作者 ID: 808611

MD, PhD, Research Associate of the Department of Foot Pathology, Neuroorthopedics and Systemic Diseases

俄罗斯联邦, 64, Parkovaya str., Saint-Petersburg, Pushkin, 196603

Tatyana Prokopenko

The Turner Scientific Research Institute for Children’s Orthopedics

Email: prokopenkotn@mail.ru
ORCID iD: 0000-0002-0498-2510

MD, Pediatrician of the Consultative and Diagnostic Center

俄罗斯联邦, 64, Parkovaya str., Saint-Petersburg, Pushkin, 196603

Artur Bergaliev

The Turner Scientific Research Institute for Children’s Orthopedics

Email: bergaliev2006@mail.ru
ORCID iD: 0000-0003-1415-6826

MD, PhD, D.Sc., Radiologist

俄罗斯联邦, 64, Parkovaya str., Saint-Petersburg, Pushkin, 196603

Stanislav Ivanov

The Turner Scientific Research Institute for Children’s Orthopedics

Email: ortostas@mail.ru
ORCID iD: 0000-0002-2187-3973

MD, PhD, Head of the Department of Cerebral Palsy and the Spina Bifida Сenter

俄罗斯联邦, 64, Parkovaya str., Saint-Petersburg, Pushkin, 196603

Tatyana Kiseleva

The Turner Scientific Research Institute for Children’s Orthopedics

Email: orthokis@mail.ru

MD, Orthopedic and Trauma Surgeon of the Department of Foot and Ankle Surgery, Neuroorthopedics and Skeletal Dysplasias

俄罗斯联邦, 64, Parkovaya str., Saint-Petersburg, Pushkin, 196603

参考

  1. Yaşar E, Adigüzel E, Arslan M, Matthews DJ. Basics of bone metabolism and osteoporosis in common pediatric neuromuscular disabilities. Eur J Paediatr Neurol. 2018;22(1):17-26. https://doi.org/10.1016/ j.ejpn.2017.08.001.
  2. Кенис В.М., Богданова С.Л., Прокопенко Т.Н., и др. Биомаркеры метаболизма костной ткани у детей с церебральным параличом, способных к передвижению // Ортопедия, травматология и восстановительная хирургия детского возраста. – 2019. – Т. 7. – № 4. – С. 79–86. [Kenis VM, Bogdanova SL, Prokopenko TN. Bone metabolism biomarkers in walking children with cerebral palsy. Pediatric traumatology, orthopaedics and reconstructive surgery. 2019;7(4):79-86. (In Russ.)]. https://doi.org/10.17816/PTORS7479-86.
  3. Houlihan CM, Stevenson RD. Bone density in cerebral palsy. Phys Med Rehabil Clin N Am. 2009;20(3):493-508. https://doi.org/10.1016/j.pmr.2009.04.004.
  4. Moon SJ, An YM, Kim SK, et al. The effect of low-dose intravenous bisphosphonate treatment on osteoporosis in children with quadriplegic cerebral palsy. Korean J Pediatr. 2017;60(12):403-407. https://doi.org/10.3345/kjp.2017.60.12.403.
  5. Иванов С.В., Кенис В.М., Прокопенко Т.Н., и др. Переломы нижних конечностей у детей с последствиями спинномозговых грыж // Ортопедия, травматология и восстановительная хирургия детского возраста. – 2018. – Т. 6. – № 3. – С. 25–31. [Ivanov SV, Kenis VM, Prokopenko TN, et al. Fractures of lower limbs in children with spina bifida. Pediatric traumatology, orthopaedics and reconstructive surgery. 2018;6(3):25-31. (In Russ.)]. https://doi.org/10.17816/PTORS6325-31.
  6. Bass SL, Naughton G, Saxon L, et al. Exercise and calcium combined results in a greater osteogenic effect than either factor alone: a blinded randomized placebo-controlled trial in boys. J Bone Miner Res. 2007;22(3):458-464. https://doi.org/10.1359/jbmr.061201.
  7. Kilpinen-Loisa P, Nenonen H, Pihko H, Makitie O. High-dose vitamin D supplementation in children with cerebral palsy or neuromuscular disorder. Neuropediatrics. 2007;38(4):167-172. https://doi.org/10.1055/s-2007-990266.
  8. Kim MJ, Kim SN, Lee IS, et al. Effects of bisphosphonates to treat osteoporosis in children with cerebral palsy: a meta-analysis. J Pediatr Endocrinol Metab. 2015;28(11-12):1343-1350. https://doi.org/10.1515/jpem-2014-0527.
  9. Fehlings D, Switzer L, Agarwal P, et al. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Dev Med Child Neurol. 2012;54(2):106-116. https://doi.org/10.1111/j.1469-8749.2011.04091.x.
  10. Marreiros HF, Loff C, Calado E. Osteoporosis in paediatric patients with spina bifida. J Spinal Cord Med. 2012;35(1):9-21. https://doi.org/10.1179/2045772311Y.0000000042.
  11. Lewiecki EM, Gordon CM, Baim S, et al. Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int. 2008;19(10):1369-1378. https://doi.org/10.1007/s00198-008-0689-9.
  12. Кенис В.М., Иванов С.В., Киселева Т.И., и др. Переносимость и безопасность применения бисфосфонатов у детей с детским церебральным параличом // Детская и подростковая реабилитация. – 2018. – № 3. – С. 28–33. [Kenis VM, Ivanov SV, Kiseleva TI, et al. Tolerability and safety of bisphosphonates in children with cerebral palsy. Detskaya i podrostkovaya reabilitatsiya. 2018;(3):28-33. (In Russ.)]
  13. Henderson RC, Lark RK, Kecskemethy HH, et al. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr. 2002;141(5):644-651. https://doi.org/10.1067/mpd.2002.128207.
  14. Bachrach SJ, Kecskemethy HH, Harcke HT, et al. Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy. J Clin Densitom. 2006;9(2):167-174. https://doi.org/10.1016/ j.jocd.2005.11.003.
  15. Plotkin H, Coughlin S, Kreikemeier R, et al. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Dev Med Child Neurol. 2006;48(9):709-712. https://doi.org/10.1017/S0012162206001526.
  16. Paksu MS, Vurucu S, Karaoglu A, et al. Osteopenia in children with cerebral palsy can be treated with oral alendronate. Childs Nerv Syst. 2012;28(2):283-286. https://doi.org/10.1007/s00381-011-1576-9.
  17. Damilakis J. et al. Pediatric radiation dose and risk from bone density measurements using a GE Lunar Prodigy scanner. Osteoporos Int. 2013;24(7):2025-2031. https://doi.org/10.1007/s00198-012-2261-x.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Kenis V., Sapogovskiy A., Prokopenko T., Bergaliev A., Ivanov S., Kiseleva T., 2020

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).